Internship

Intern – MBA Finance Program

2025

Posted on 8/30/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

No H1B Sponsorship

Princeton, NJ, USA

Onsite presence is essential for collaboration and productivity.

US Citizenship Required

Category
Corporate Finance
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Financial analysis
Requirements
  • Candidates should expect to receive a Masters in Business Administration degree during the following school year, scheduled to graduate by the Spring of 2026.
  • The ideal candidate will have 3 to 5 years’ work experience and strong intellectual, financial and analytical skills with demonstrated ability for quickly grasping new and complex concepts.
  • Strong interpersonal skills, including the ability to influence others and work effectively in a matrix organization, are essential.
  • Leadership potential is highly valued, and a commitment to integrity, professionalism and teamwork is required.
  • Successful candidates will also demonstrate superior financial modeling skills, specifically in Excel, and the ability to quickly learn financial/accounting software.
  • Candidates must be a US citizen, have a lawful permanent resident of the US or otherwise authorized to work in the US without requiring sponsorship now or in the future.
Responsibilities
  • development of operating budgets
  • R&D portfolio allocation
  • financial forecasting for compounds in development
  • financial analysis of operating performance and return on capital expenditures
  • work on a specific brand where they team up with marketing to manage the brand P&L and develop strategic initiatives for growing the business.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with AI Proteins could expand BMS's therapeutic portfolio with miniprotein-based therapeutics.
  • FDA approval for Opdivo in NSCLC treatment strengthens BMS's position in lung cancer therapies.
  • Licensing agreement with Prime Medicine enhances BMS's cell and gene therapy capabilities.

What critics are saying

  • Legal challenges from the lawsuit against HRSA and HHS could harm BMS's reputation.
  • Refiling of the $6.4 billion lawsuit by UMB poses potential financial liabilities.
  • Competitive pressure in oncology as Opdivo faces competition from other PD-1 inhibitors.

What makes Bristol-Myers Squibb unique

  • BMS focuses on innovative medicines in oncology, immunology, and cardiovascular diseases.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE